AR062647A1 - Formulaciones farmaceutica y metodos de uso - Google Patents
Formulaciones farmaceutica y metodos de usoInfo
- Publication number
- AR062647A1 AR062647A1 ARP060100226A ARP060100226A AR062647A1 AR 062647 A1 AR062647 A1 AR 062647A1 AR P060100226 A ARP060100226 A AR P060100226A AR P060100226 A ARP060100226 A AR P060100226A AR 062647 A1 AR062647 A1 AR 062647A1
- Authority
- AR
- Argentina
- Prior art keywords
- pregabalin
- gabapentin
- active ingredient
- group
- ingredient selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones farmacéuticas, y con nuevos usos médicos de la gabapentina y la pregabalina. Las formulaciones pueden contener hasta tres componentes, incluyendo un componente de liberacion inmediata, un componente de liberacion sostenida y un componente de liberacion retardada. La proporcion de cada componente presente en la formulacion puede ser ajustada para obtener una AUC y efectos terapéuticos deseados después de la administracion oral en sujetos humanos. Reivindicacion 1: Una composicion que comprende: (a) un ingrediente activo seleccionado del grupo formado por gabapentina y pregabalina con una cubierta de excipiente polimérico soluble independiente del pH. (b) un ingrediente activo seleccionado del grupo formado por gabapentina y pregabalina con una cubierta de excipiente polimérico insoluble independiente del pH, (c) un ingrediente activo seleccionado del grupo formado por gabapentina y pregabalina con una cubierta de excipiente polimérico soluble dependiente del pH.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64585705P | 2005-01-21 | 2005-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062647A1 true AR062647A1 (es) | 2008-11-26 |
Family
ID=36692870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100226A AR062647A1 (es) | 2005-01-21 | 2006-01-20 | Formulaciones farmaceutica y metodos de uso |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1838291A4 (es) |
JP (1) | JP2008528494A (es) |
KR (1) | KR20070116588A (es) |
CN (1) | CN101137352A (es) |
AR (1) | AR062647A1 (es) |
AU (1) | AU2006206423A1 (es) |
BR (1) | BRPI0614021A2 (es) |
CA (1) | CA2595470A1 (es) |
IL (1) | IL184735A0 (es) |
MX (1) | MX2007008833A (es) |
TW (1) | TW200640497A (es) |
WO (1) | WO2006078811A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009006575A (es) | 2006-12-22 | 2009-07-02 | Recordati Ireland Ltd | Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids). |
DK2596784T3 (en) * | 2007-11-23 | 2017-03-06 | Gruenenthal Gmbh | Tapentadol compositions |
EP2217217B1 (en) | 2007-11-23 | 2018-05-30 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
MX2013007884A (es) | 2011-01-07 | 2013-09-13 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
WO2012150246A1 (de) * | 2011-05-05 | 2012-11-08 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur gezielten freigabe von wirkstoffen |
KR101438546B1 (ko) * | 2011-08-26 | 2014-09-17 | 근화제약주식회사 | 프레가발린을 포함하는 서방성 제제 |
WO2013100873A1 (en) * | 2011-12-19 | 2013-07-04 | Mahmut Bilgic | Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer) |
AU2012363873B2 (en) | 2012-01-06 | 2017-11-23 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
CN110693867A (zh) * | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
KR102221846B1 (ko) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
TW201613625A (en) * | 2014-08-29 | 2016-04-16 | Wakamoto Pharma Co Ltd | Lactic acid bacteria-containing composition |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
CA2953225A1 (en) | 2015-05-26 | 2016-12-01 | Isa Odidi | Controlled extended release pregabalin |
BR112018071363A2 (pt) | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de nicotinamida |
AU2017300185B2 (en) * | 2016-07-17 | 2023-02-02 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
CN112023032B (zh) * | 2020-09-14 | 2022-03-18 | 广东鼎信医药科技有限公司 | 一种含有消化酶的药物组合物及其制备方法 |
CA3199166A1 (en) | 2020-12-04 | 2022-06-09 | Cecilia Jannette Munoz Martinez | Stable, coated, and solid pharmaceutical drug composition containing an opioid analgesic and an antiepileptic to relieve pain |
CN116898819B (zh) * | 2023-06-09 | 2024-02-06 | 则正(上海)生物科技有限公司 | 一种普瑞巴林缓释剂及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
JP2001507359A (ja) * | 1997-01-03 | 2001-06-05 | エラン コーポレーション ピーエルシー | 徐放性シサプリドミニ錠剤製剤 |
FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
US20030224050A1 (en) * | 2002-01-04 | 2003-12-04 | Charles Chiao | Drug delivery system for sustained delivery of glipizide |
EP2316468A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
JP2008530131A (ja) * | 2005-02-15 | 2008-08-07 | ジャズ、ファーマシューティカルズ、インコーポレイテッド | 置換ピラジン化合物の徐放のための投薬形態および方法 |
-
2006
- 2006-01-20 JP JP2007552260A patent/JP2008528494A/ja active Pending
- 2006-01-20 EP EP06718892A patent/EP1838291A4/en not_active Withdrawn
- 2006-01-20 KR KR1020077019105A patent/KR20070116588A/ko not_active Application Discontinuation
- 2006-01-20 AR ARP060100226A patent/AR062647A1/es not_active Application Discontinuation
- 2006-01-20 AU AU2006206423A patent/AU2006206423A1/en not_active Abandoned
- 2006-01-20 CN CNA2006800065476A patent/CN101137352A/zh active Pending
- 2006-01-20 BR BRPI0614021-1A patent/BRPI0614021A2/pt not_active IP Right Cessation
- 2006-01-20 CA CA002595470A patent/CA2595470A1/en not_active Abandoned
- 2006-01-20 TW TW095102217A patent/TW200640497A/zh unknown
- 2006-01-20 WO PCT/US2006/001887 patent/WO2006078811A2/en active Application Filing
- 2006-01-20 MX MX2007008833A patent/MX2007008833A/es not_active Application Discontinuation
-
2007
- 2007-07-19 IL IL184735A patent/IL184735A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200640497A (en) | 2006-12-01 |
MX2007008833A (es) | 2008-03-25 |
CN101137352A (zh) | 2008-03-05 |
AU2006206423A1 (en) | 2006-07-27 |
EP1838291A4 (en) | 2008-12-03 |
WO2006078811A2 (en) | 2006-07-27 |
CA2595470A1 (en) | 2006-07-27 |
EP1838291A2 (en) | 2007-10-03 |
KR20070116588A (ko) | 2007-12-10 |
IL184735A0 (en) | 2007-12-03 |
WO2006078811A3 (en) | 2007-03-01 |
BRPI0614021A2 (pt) | 2011-03-01 |
JP2008528494A (ja) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062647A1 (es) | Formulaciones farmaceutica y metodos de uso | |
ES2641821T3 (es) | Forma de dosificación sólida de disolución rápida | |
AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
EP2422794A3 (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
WO2007128923A3 (fr) | Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation | |
AR053680A1 (es) | Composicion | |
AR048705A1 (es) | Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
EP4218724A3 (en) | Microstructure array for delivery of active agents | |
NO20070887L (no) | Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet | |
DE60121301D1 (de) | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen | |
AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
WO2009071219A2 (en) | Oral dispersable tablet | |
WO2008061226A3 (en) | Sustained-release formulations of topiramate | |
PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
ATE504288T1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
AR053977A1 (es) | Composiciones farmaceuticas con enmascaramiento de sabor | |
AU2008262031B2 (en) | Extended release formulation of nevirapine | |
CN111904926A (zh) | 局部用双氯芬酸钠组合物 | |
US20060079640A1 (en) | Adhesive composition for dermal patch and production process thereof | |
WO2021201266A1 (ja) | 短時間溶解マイクロニードル | |
TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
PT1305057E (pt) | Composicao de biomateria microparticular para uso medicinal | |
PA8615501A1 (es) | Formulaciones farmaceuticas transdermicas | |
RU2711090C2 (ru) | Неокрашивающая гелевая композиция, содержащая нимесулид, для местного применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |